NEW YORK, NY / ACCESSWIRE / March 14, 2018 / Both Valeant Pharmaceuticals and Johnson & Johnson saw gains on Tuesday with little news to explain the moves. Recently Johnson & Johnson acquired Orthotaxy to develop a robot-assisted orthopedics surgery platform. Valeant announced an upsize of cash tender offers earlier in the week.

RDI Initiates Coverage on:

Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/report/?ticker=VRX

Johnson & Johnson
https://rdinvesting.com/report/?ticker=JNJ

Valeant Pharmaceuticals International, Inc. shares closed up 1.84% on almost 8.6 million shares traded. It was yesterday that the company announced that its wholly owned indirect subsidiary, has priced its previously announced offering of 9.250% senior notes due 2026. The aggregate size of the offering has been increased by $250,000,000 from the previously announced offering size of $1,250,000,000 to $1,500,000,000. The offering is expected to close on or about March 26th. It was last month that the company saw losses after reporting fourth quarter financial results that missed on revenue and a grim 2018 guidance. Earnings for the fourth quarter were $513 million, or $1.45 per share. For 2017, the company's adjusted EPS came to $6.83. Analysts had been waiting for $3.89. Revenue was a miss at $2.16 billion while analysts were waiting for $2.18 billion.

Access RDI's Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/report/?ticker=VRX

Johnson & Johnson shares closed up 1.30% on Tuesday with a little over 9.1 million shares traded. It was last month that the company announced that it has acquired Orthotaxy, through Apsis, its French subsidiary. The acquisition is so that the company can develop its robot-assisted orthopedics surgery platform. There was no price given for how much Johnson & Johnson paid, but the company wants to build a comprehensive orthopedics platform and robotic-assisted surgical technology will play a big part. Founded in 2009, Orthotaxy is developing an early-stage total and partial knee replacement technology. Through purchasing the company, Johnson & Johnson will be able to offer a cost-effective user-friendly and time-friendly robot assisted orthopedic surgery solution. Ciro Römer, the company group chairman of DePuy Synthes, the orthopedics division of Johnson & Johnson, stated, "Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopedics platform, delivering value to patients, physicians and healthcare providers across the episode of care. The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction."

Access RDI's Johnson & Johnson Research Report at:
https://rdinvesting.com/report/?ticker=JNJ

Our Actionable Research on Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Johnson & Johnson (NYSE: JNJ) and can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com